PuraPharm Corporation Limited (1498.HK)
HKD 0.55
(-3.51%)
HKD 0.55
(-3.51%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 406.85 Million HKD | -9.2% |
| 2022 | 448.06 Million HKD | -32.07% |
| 2021 | 659.59 Million HKD | 9.6% |
| 2020 | 601.81 Million HKD | -13.52% |
| 2019 | 695.87 Million HKD | -6.66% |
| 2018 | 745.5 Million HKD | 26.02% |
| 2017 | 591.56 Million HKD | 10.37% |
| 2016 | 535.98 Million HKD | 13.1% |
| 2015 | 473.9 Million HKD | 29.36% |
| 2014 | 366.35 Million HKD | 7.03% |
| 2013 | 342.3 Million HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 207.62 Million HKD | -1.96% |
| 2023 Q2 | 195.08 Million HKD | -10.23% |
| 2023 FY | 406.85 Million HKD | -9.2% |
| 2023 Q4 | 211.77 Million HKD | 8.56% |
| 2022 FY | 448.06 Million HKD | -32.07% |
| 2022 Q4 | 217.3 Million HKD | -5.83% |
| 2022 Q2 | 230.76 Million HKD | -35.33% |
| 2021 Q2 | 302.75 Million HKD | -5.8% |
| 2021 FY | 659.59 Million HKD | 9.6% |
| 2021 Q4 | 356.83 Million HKD | 17.86% |
| 2020 Q2 | 280.43 Million HKD | -22.6% |
| 2020 FY | 601.81 Million HKD | -13.52% |
| 2020 Q4 | 321.38 Million HKD | 14.6% |
| 2019 FY | 695.87 Million HKD | -6.66% |
| 2019 Q2 | 333.55 Million HKD | -7.06% |
| 2019 Q4 | 362.32 Million HKD | 8.62% |
| 2018 FY | 745.5 Million HKD | 26.02% |
| 2018 Q4 | 358.89 Million HKD | -7.17% |
| 2018 Q2 | 386.6 Million HKD | 17.7% |
| 2017 Q2 | 263.09 Million HKD | -18.73% |
| 2017 Q4 | 328.47 Million HKD | 24.85% |
| 2017 FY | 591.56 Million HKD | 10.37% |
| 2016 FY | 535.98 Million HKD | 13.1% |
| 2016 Q2 | 212.24 Million HKD | -26.05% |
| 2016 Q4 | 323.73 Million HKD | 52.53% |
| 2015 Q2 | 186.9 Million HKD | -11.31% |
| 2015 FY | 473.9 Million HKD | 29.36% |
| 2015 Q4 | 286.99 Million HKD | 53.56% |
| 2014 Q4 | 210.74 Million HKD | 35.44% |
| 2014 FY | 366.35 Million HKD | 7.03% |
| 2014 Q2 | 155.6 Million HKD | 69.9% |
| 2013 FY | 342.3 Million HKD | 0.0% |
| 2013 Q4 | 91.58 Million HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -56.993% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 96.136% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -588.448% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | 48.097% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 57.676% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 61.363% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 76.159% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | 49.715% |
| SSY Group Limited | 6.46 Billion HKD | 93.705% |
| JBM (Healthcare) Limited | 648.41 Million HKD | 37.253% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 72.281% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.85% |